News Novartis/Amgen migraine drug reduces attacks after others fa... Aimovig notches up another late-stage trial success
News Lilly chases Amgen with migraine drug filing Eli Lilly has filed its galcanezumab migraine drug with the FDA, as it looks to claim second place among a group of companies attempting to market a new class of therapies.
News Teva plans migraine drug filing later this year Blockbuster hopeful could launch next year if approved.
Oncology CAR-T therapies: Faster, better, cheaper In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends